A panelist discusses how patient-reported outcomes and real-world evidence contribute valuable insights into the practical impact of these treatments, complementing traditional efficacy measures and helping inform clinical decision-making in actual practice settings.
The panelist discusses how, expanding clinical trials, biomarker testing, and financial support improves access to emerging EGFR therapies. Novel bispecific antibodies and ADCs may shift treatment. Key insights include resistance monitoring and proactive AE management.
An expert discusses the design and objectives of the Phase 3 PEACE-3 study, which evaluates the combination of enzalutamide (ENZA) and radium-223 (Ra-223) for ARPI-naïve metastatic castration-resistant prostate cancer (mCRPC).
An expert discusses how, in third line (3L) therapy, goals shift from optimal disease control to managing treatment-resistant disease while preserving quality of life. Unlike 2L therapy where significant disease control is still expected, 3L aims for modest clinical benefit, symptomatic relief, and stabilizing disease progression. Treatment choices now heavily prioritize tolerability, patient preferences, and palliative considerations.
The panelist discusses first-line options including atezolizumab plus bevacizumab, lenvatinib, and sorafenib. Second-line treatments include regorafenib, cabozantinib, and ramucirumab. Clinical trials should be prioritized when available.
An expert discusses the patient case of a 65-year-old woman who has presented to the emergency department with abdominal pain. The patient’s previous medical issues include a duodenal ulcer that she experienced 10 years ago. The patient is a smoker, and her current medication is lansoprazole (30 mg). After the patient begins to present worsening lower back pain, a CT scan shows lytic lesions in her thoracic spine and rounded lesion in both lungs. A biopsy of the lung lesion confirms clear cell renal cell carcinoma (RCC) with sarcomatoid differentiation.
The panelist discusses the case of a 60-year-old man diagnosed with unresectable hepatocellular carcinoma (HCC). The patient has a history of metabolic dysfunction-associated steatohepatitis managed with lifestyle changes and medication. Initially, there was no clinical or radiographic evidence of cirrhosis. The patient recently presented to his gastroenterologist complaining of abdominal pain in the upper right quadrant and fatigue.
An expert discusses the design and objectives of the PEACE-3 study, which investigates the combination of enzalutamide and radium-223 for ARPI-naïve metastatic castration-resistant prostate cancer (mCRPC).
A panelist discusses how the CONTACT-03 and TiNivo-2 studies yielded important insights about ICI rechallenge and tivozanib in the post-ICI setting, with particular attention to the notable 9.2-month median PFS with tivozanib monotherapy, the impact of dosing strategies, and the timing of therapy initiation, though questions remain about the broader implications for ICI rechallenge efficacy across different treatment contexts.
The panelist discusses how, Healthcare professionals use osimertinib 1L for EGFR-mutated NSCLC, re-testing at progression for resistance mutations. MARIPOSA data refine 1L choices by predicting resistance pathways, guiding optimal sequencing.
Panelists discuss the efficacy and safety of KRAS inhibitors for non–-small cell lung cancer (NSCLC), evaluating clinical trial results and their potential impact on treatment strategies.
Panelists discuss second-line treatment decision-making for KRAS-mutated metastatic non–-small cell lung cancer (NSCLC), focusing on available therapies and personalized approaches based on patient characteristics.
Panelists discuss how treatment sequencing decisions in myelofibrosis should be guided by clinical evidence, patient response patterns, and strategic consideration of future therapeutic options to maintain long-term disease control.
Panelists discuss how the timing of therapeutic interventions in early-stage myelofibrosis must be carefully weighed against potential risks and benefits, with consideration of disease trajectory and patient-specific factors to optimize long-term outcomes.
Panelists discuss how CARTITUDE-4 demonstrated superior progression-free survival and overall response rates with ciltacabtagene autoleucel (cilta-cel) compared with standard treatment options in relapsed/refractory multiple myeloma (R/R MM) patients who received 1 to 3 prior lines of therapy.
Panelists discuss how to address practical challenges in delivering chimeric antigen receptor (CAR) T cell therapy, including patient selection, bridging therapy, manufacturing delays, access barriers, and coordination of care to optimize real-world outcomes.
An expert discusses the therapeutic options included in the NCCN guidelines for metastatic castration-resistant prostate cancer, such as abiraterone (ABI) based on COU-AA-301 and enzalutamide (ENZA) based on AFFIRM.
A panelist discusses how second-line treatment options for kidney cancer have evolved through multiple clinical trials including Study 205, METEOR, CONTACT-03, TIVO-3, TiNivo-2, and LITESPARK-005, which have demonstrated varying efficacy across different patient populations and prior therapies, particularly noting the impact of prior immunotherapy exposure on treatment selection and the need for careful consideration of historical trial data in the context of modern treatment paradigms.
An expert discusses the case of a patient with metastatic castration-resistant prostate cancer (CRPC) who progressed after treatment with androgen receptor pathway inhibitors (ARPI) and docetaxel for localized prostate cancer.
The panelist discusses how, Healthcare professionals manage distinct toxicities with ami+laz (IRRs, rash) and osi+chemotherapyctx (cytopenias, diarrhea, fatigue). SKIPPirr informs IRR mitigation in ami’s first infusion. Proactive AE strategies include premedication, dose adjustments, supportive care, and monitoring.
The panelist discusses how, regarding the patient case, she will review the FDA approved options for the patient, including the combination of amivantamab + Lazertinib, osimertinib/chemotherapy, or single agent osimertinib.
A panelist discusses how second-line therapy goals typically shift from pursuing complete remission (as in first-line treatment) to focusing more on disease control, quality of life management, and balancing treatment effectiveness with tolerability based on the patient's prior therapy experience.
Panelists discuss first-line treatment decision-making for KRAS-mutated metastatic non–-small cell lung cancer (NSCLC), focusing on the selection of targeted therapies and factors influencing clinical choices.
Panelists discuss the use of RNA-based molecular panels in metastatic non–-small cell lung cancer (NSCLC), highlighting their role in guiding personalized treatment decisions and improving patient outcomes.
Panelists discuss how complex cases of advanced myelofibrosis can be managed using evidence-based treatment algorithms, considering factors such as disease progression, prior therapies, and challenging complications.
Panelists discuss how clinicians can effectively manage patients with high-risk myelofibrosis with cytopenias through careful treatment selection, dose modification strategies, and monitoring of hematologic parameters.
Panelists discuss how to manage an aggressive case of early posttransplant progression in a young woman with functionally high-risk multiple myeloma (MM), focusing on rapid intervention strategies and novel therapeutic approaches to overcome poor prognosis disease.
Panelists discuss how to approach treatment selection and sequencing for a 58-year-old woman with high-risk multiple myeloma (MM) who has developed progressive disease after stem cell transplantation, considering factors such as prior therapy exposure, available options, and disease biology.
Panelists discuss decision-making in metastatic non–-small cell lung cancer (NSCLC) when molecular testing results are delayed, focusing on strategies to optimize treatment while awaiting results.
Panelists discuss the role of molecular testing in metastatic non–-small cell lung cancer (NSCLC), emphasizing its importance in identifying actionable mutations and guiding personalized treatment strategies.